Skip to main content
. 2024 Nov 27;26:e55185. doi: 10.2196/55185

Table 2.

Description of the development and external validation cohorts. Baseline characteristics were compared by the chi-square test for categorical data and by the Kruskal-Wallis test for continuous data.


Development (n=824) Temporal validation (n=350) Geographic validation (n=119) P value
Study period 2017-2019 2021-2022 2022 a
Patient-related factors

Sex, n (%)


Female 385 (46.7) 199 (56.9) 66 (55.5) .003

Age (years), median (IQR) 69 (55-80) 67 (55-79) 69 (55-78) .91

Language, n (%) .68


Dutch 810 (98.3) 347 (99.1) 118 (99.2)


French 11 (1.3) 3 (0.9) 1 (0.8)


English 3 (0.4) 0 (0) 0 (0)

Residence before admission, n (%) .37


Home 798 (95.8) 341 (97.4) 116 (97.5)


Nursing home 29 (3.5) 9 (2.6) 2 (1.7)


Other 6 (0.7) 0 (0) 1 (0.8)

ESIbtriage score, n (%) <.001


1 1 (0.1) 5 (1.4) 0 (0)


2 117 (14.2) 102 (29.1) 14 (11.8)


3 175 (21.2) 116 (33.1) 91 (76.5)


4 14 (21.7) 19 (5.4) 14 (11.8)


5 3 (0.4) 1 (0.3) 0 (0)


Unknown 75 (9.1) 107 (30.6) 0 (0)

Transport to the EDc, n (%) <.001


Patient’s own transport 706 (85.7) 243 (69.4) 76 (63.9)


Ambulance 97 (11.8) 80 (22.9) 25 (21.0)


Emergency physician vehicle transport 21 (2.5) 27 (7.7) 18 (15.1)
Drug-related factors

Number of medications reported by the ED physician per patient at time of ED visit, median (IQR) 6 (3-10) 5 (3-9) 6 (3-9) .23

Number of medications reported by the ED physician per patient at time of ED visit by first-level ATCd group, median (IQR)


ATC A drugs (alimentary tract and metabolism) 1 (0-2) 1 (0-3) 1 (0-2) .74


ATC B (blood and blood forming agents) 1 (0-1) 1 (0-1) 0 (0-1) .18


ATC C (cardiovascular system) 1 (0-3) 1 (0-2) 1 (0-2) .88


ATC D (dermatologicals) 0 (0-0) 0 (0-0) 0 (0-0) .08


ATC G (genito urinary system and sex hormones) 0 (0-0) 0 (0-0) 0 (0-0) .34


ATC H (systemic hormonal preparations, excl. sex hormones and insulins) 0 (0-0) 0 (0-0) 0 (0-0) .57


ATC J (anti-infectives for systemic use) 0 (0-0) 0 (0-0) 0 (0-0) .004


ATC L (antineoplastic and immunomodulating agents) 0 (0-0) 0 (0-0) 0 (0-0) .60


ATC M (musculo-skeletal system) 0 (0-0) 0 (0-0) 0 (0-0) .04


ATC N (nervous system) 1 (0-2) 1 (0-2) 1 (0-2) .28


ATC P (antiparasitic products, insecticides, and repellents) 0 (0-0) 0 (0-0) 0 (0-0) .20


ATC R (respiratory system) 0 (0-0) 0 (0-0) 0 (0-0) .72


ATC S (sensory organs) 0 (0-0) 0 (0-0) 0 (0-0) .007


ATC V (various) 0 (0-0) 0 (0-0) 0 (0-0) .39
ED visit related factors

Specialty of the ED physician, n (%) <.001


Emergency medicine 107 (13.0) 61 (17.4) 19 (16.0)


Internal medicine 569 (69.0) 254 (72.6) 77 (64.7)


Surgery 148 (18.0) 35 (10) 21 (17.6)


Psychiatry 0 (0) 0 (0) 2 (1.7)

Time of ED visit, n (%) <.001


Morning 340 (41.3) 157 (44.9) 81 (68.0)


Afternoon 137 (16.6) 33 (9.4) 16 (13.4)


Evening 260 (31.5) 60 (17.1) 1 (0.8)


Night 87 (10.5) 100 (28.6) 21 (17.6)
Medication reconciliation-related factors, n (%)

Availability of regional shared electronic medication record (yes) 111 (13.5) 80 (22.9) 46 (38.6) <.001

Electronic validation of the medication history by the ED physician (yes) 155 (18.8) 63 (18.0) 31 (26.0) .14
Outcome, n (%)

At least 1 clinically relevant medication discrepancy, (yes) 287 (35) 131 (37) 58 (49) .01

aNot applicable.

bESI: Emergency Severity Index.

cED: emergency department.

dATC: Anatomical Therapeutic Chemical.